Christiansen, Helle http://orcid.org/0000-0003-4893-4622
Thirstrup, Steffen
Hallgreen, Christine Erikstrup
Funding for this research was provided by:
h. lundbeck a/s
Article History
Received: 21 June 2021
Accepted: 8 November 2021
First Online: 7 February 2022
Declarations
:
: This study was carried out under the umbrella of the Copenhagen Centre for Regulatory Science (CORS). CORS is a cross-faculty university-anchored institution involving various public bodies (Danish Medicines Agency, Copenhagen University) and private stakeholders (Novo Nordisk, Lundbeck, Ferring pharmaceuticals, LEO pharma) as well as patient organisations (Rare Diseases Denmark). The centre is purely devoted to the scientific aspects of the regulatory field and has a patient-oriented focus. The research is not a company-specific product or directly company related. Steffen Thirstrup is a full-time employee of NDA Group and does not receive consulting fees directly from clients.